Seattle Genetics Highlights Data from SGN-CD19A Antibody-Drug Conjugate Program at #ASH2015

Seattle Genetics, Inc.

today highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL), presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015. Preclinical data from a novel antibody-drug conjugate (ADC) program called SGN-CD19B in B-cell malignancies will also be featured in an oral presentation. About 85 percent of non-Hodgkin lymphomas (NHL) are B-cell lineage, and CD19 is broadly expressed across all subtypes of B-cell malignancies. These two ADCs, 19A and SGN-CD19B, both target CD19 and utilize two of Seattle Genetics' proprietary payloads, monomethyl auristatin F (MMAF) and a